Thyrocare Technologies Ltd
Thyrocare Technologies is engaged in the business of healthcare industry and is involved in providing quality diagnostic services at affordable costs to patients, laboratories and hospitals in India.
- Market Cap ₹ 5,212 Cr.
- Current Price ₹ 980
- High / Low ₹ 1,055 / 571
- Stock P/E 57.4
- Book Value ₹ 103
- Dividend Yield 1.84 %
- ROCE 26.0 %
- ROE 16.9 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 135%
Cons
- Stock is trading at 9.50 times its book value
- The company has delivered a poor sales growth of 9.62% over past five years.
- Promoters have pledged 100% of their holding.
- Working capital days have increased from 48.6 days to 89.8 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Part of BSE Healthcare BSE SmallCap BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|
183 | 241 | 304 | 356 | 403 | 434 | 495 | 589 | 527 | 572 | 687 | |
110 | 147 | 189 | 212 | 249 | 261 | 323 | 353 | 403 | 432 | 498 | |
Operating Profit | 73 | 94 | 115 | 145 | 154 | 174 | 171 | 236 | 123 | 140 | 189 |
OPM % | 40% | 39% | 38% | 41% | 38% | 40% | 35% | 40% | 23% | 24% | 27% |
8 | 7 | -15 | 21 | 11 | 1 | 12 | 29 | 9 | 9 | 15 | |
Interest | 0 | 1 | 0 | 0 | 1 | 2 | 1 | 3 | 5 | 6 | 3 |
Depreciation | 13 | 18 | 18 | 20 | 26 | 32 | 30 | 34 | 39 | 47 | 55 |
Profit before tax | 68 | 82 | 82 | 145 | 138 | 140 | 152 | 228 | 89 | 96 | 145 |
Tax % | 35% | 37% | 48% | 36% | 38% | 37% | 26% | 23% | 27% | 28% | 38% |
44 | 52 | 43 | 93 | 85 | 88 | 113 | 176 | 64 | 69 | 91 | |
EPS in Rs | 8.95 | 9.64 | 7.98 | 17.36 | 16.13 | 16.73 | 21.40 | 33.29 | 12.18 | 13.36 | 17.27 |
Dividend Payout % | 171% | 104% | 125% | 58% | 124% | 30% | 117% | 45% | 148% | 135% | 122% |
Compounded Sales Growth | |
---|---|
10 Years: | 14% |
5 Years: | 10% |
3 Years: | 5% |
TTM: | 20% |
Compounded Profit Growth | |
---|---|
10 Years: | 8% |
5 Years: | 0% |
3 Years: | -17% |
TTM: | 29% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 13% |
3 Years: | 13% |
1 Year: | 54% |
Return on Equity | |
---|---|
10 Years: | 19% |
5 Years: | 20% |
3 Years: | 14% |
Last Year: | 17% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 51 | 54 | 54 | 54 | 53 | 53 | 53 | 53 | 53 | 53 | 53 |
Reserves | 226 | 312 | 354 | 390 | 382 | 314 | 374 | 474 | 481 | 474 | 494 |
0 | 0 | 0 | 0 | 2 | 12 | 8 | 21 | 23 | 42 | 25 | |
53 | 44 | 30 | 36 | 37 | 90 | 106 | 60 | 74 | 75 | 121 | |
Total Liabilities | 329 | 410 | 438 | 479 | 475 | 469 | 541 | 607 | 632 | 644 | 693 |
196 | 259 | 259 | 299 | 294 | 269 | 253 | 285 | 294 | 306 | 297 | |
CWIP | 6 | 1 | 17 | 0 | 1 | 5 | 8 | 3 | 2 | 3 | 14 |
Investments | 86 | 93 | 104 | 120 | 95 | 90 | 126 | 146 | 144 | 162 | 162 |
42 | 56 | 58 | 60 | 84 | 105 | 154 | 173 | 192 | 173 | 220 | |
Total Assets | 329 | 410 | 438 | 479 | 475 | 469 | 541 | 607 | 632 | 644 | 693 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|
34 | 68 | 90 | 107 | 100 | 168 | 115 | 113 | 129 | 168 | 191 | |
-18 | -18 | -42 | -43 | -12 | 1 | -49 | -24 | -39 | -91 | -53 | |
-23 | -45 | -49 | -64 | -94 | -165 | -62 | -89 | -86 | -85 | -130 | |
Net Cash Flow | -6 | 5 | -0 | -0 | -5 | 4 | 4 | 0 | 4 | -8 | 8 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 10 | 11 | 8 | 10 | 11 | 14 | 33 | 58 | 59 | 28 | 39 |
Inventory Days | 48 | 56 | 65 | 66 | 60 | 64 | 52 | 53 | 62 | 104 | 89 |
Days Payable | 5 | 10 | 6 | 25 | 25 | 68 | 56 | 36 | 54 | 88 | 146 |
Cash Conversion Cycle | 53 | 57 | 67 | 50 | 46 | 10 | 29 | 75 | 67 | 44 | -18 |
Working Capital Days | 28 | 2 | 19 | 10 | 28 | -5 | 21 | 44 | 36 | 20 | 90 |
ROCE % | 24% | 28% | 33% | 30% | 35% | 36% | 42% | 17% | 18% | 26% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
7h - Attached is herewith Intimation for Allotment of Equity Shares in view of the exercise of Stock Options
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
15 May - Thyrocare's Annual Secretarial Compliance Report for FY 2024-25 confirms full regulatory compliance, no violations.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
29 Apr - Thyrocare FY'25 Q4: 20% revenue growth, 36% EBITDA margin, key acquisitions, 11,000+ franchisees, dividend INR21/share.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
24 Apr - Newspaper Advertisements of Audited Financial results for Quarter and year ended March 31, 2025.
-
Audio Recordings Of Earnings Conference Call For The Quarter And Year Ended March 31, 2025.
23 Apr - Audio recording of Q4 and FY25 earnings call available on Thyrocare's website.
Annual reports
Concalls
-
Apr 2025Transcript PPT REC
-
Jan 2025Transcript PPT
-
Oct 2024Transcript PPT
-
Jul 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
-
Aug 2021TranscriptNotesPPT
-
May 2021TranscriptNotesPPT
-
Feb 2021Transcript PPT
-
Nov 2020Transcript PPT
-
Jul 2020TranscriptNotesPPT
-
May 2020TranscriptNotesPPT
-
Feb 2020TranscriptNotesPPT
-
Nov 2019TranscriptNotesPPT
-
Aug 2019TranscriptNotesPPT
-
Jun 2019TranscriptPPT
-
May 2019TranscriptNotesPPT
-
Feb 2019Transcript PPT
-
Nov 2018Transcript PPT
-
Aug 2018Transcript PPT
-
May 2018Transcript PPT
-
Feb 2018Transcript PPT
-
Dec 2017Transcript PPT
Business Segments
1) Diagnostic Testing Services (92% in FY25 vs 94% in FY22): [1] [2] The company is one of the leading Pan-India diagnostic chains, offering a range of tests focused on early disease detection and health management. It provides 929 tests and 288 profiles, including 43 wellness packages under the “Aarogyam” brand. It processes 3 Bn investigations annually and can process 10 Bn annually. [3] [4]